Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

Study-Level Bias May Influence Bleeding Prevalence Estimates in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
Wieruszewski, Patrick M. , Wieruszewski, Patrick M , Ortoleva, Jamel P.

ASAIO Journal | July 31, 2025 | Volume: 71 | Issue: 11 | Pages: e175-e175

10.1097/mat.0000000000002526 | PMID 40742175 Get It

Evolving role of the emergency medicine pharmacist in tele-emergency medicine
Smith, Cole, Sultan, Sania, Raheem, Shazia, Mattson, Alicia E , Smith, Cole, Sultan, Sania

American Journal of Health-System Pharmacy | July 31, 2025 | Volume: 82 | Issue: 24 | Pages: 1411-1415

10.1093/ajhp/zxaf204 | PMID 40749092 Get It

Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection
Bryant, Jessica A. , Straub, Timothy J. , Pardi, Darrell S. , Litcofsky, Kevin , Kelly, Colleen , Chafee, Meghan , Cohen, Stuart H. , Khanna, Sahil , Berenson, Charles S., Wortman, Jennifer R. , Sims, Matthew , Ford, Christopher B. , Lombardo, Mary-Jane, McGovern, Barbara , Moltke, Lisa Von, Henn, Matthew R. , Hasson, Brooke , Litcofsky, Kevin D , Chafee, Meghan E , Wortman, Jennifer , Henn, Matthew R , Kraft, Colleen S.

The Journal of Infectious Diseases | July 31, 2025 | Volume: 232 | Issue: 5 | Pages: e733-e740

10.1093/infdis/jiaf408 | PMID 40751372 Get It

Abstract Background Clostridioides difficile infection (CDI) treatment guidelines suggest varied approaches for patients with first (frCDI) or multiply recurrent CDI (mrCDI). Low microbial diversity, elevated primary bile acids (BA), and low secondary BA concentrations favor germination of C. difficile spores into toxin-producing bacteria and are believed to increase rCDI risk. Greater understanding of the gastrointestinal (GI) microbiome in rCDI may inform management of the disease. We describe a post hoc comparison of GI microbiome and bile acid profiles between patients with frCDI and mrCDI in a Phase 3 open-label trial, ECOSPOR IV, of fecal microbiota spores, live-brpk (VOWST®; VOS, formerly SER-109), an orally-administered live microbiome therapeutic. Methods Patients received VOS following symptom resolution after standard-of-care antibiotics. Pretreatment baseline (within 3 days following antibiotic completion) and Week 1 post-dosing stool samples were collected for whole metagenomic sequencing and metabolomics. Diversity was calculated from MetaPhlAn2 species profiles. Concentrations of primary and secondary BAs were measured via targeted LC-MS/MS. Results rCDI rates through Week 8 were similarly low in both frCDI and mrCDI patients (6.5% versus 9.7%, respectively). Baseline microbial diversity was similarly low between frCDI and mrCDI subgroups (P > .05). Diversity and secondary BA concentrations increased in both subgroups, whereas primary BA concentrations declined following VOS dosing, leading to few differences between subgroups at Week 1. Conclusions These data suggest commonalities in microbiome disruption in patients with frCDI and mrCDI that contribute to recurrence and suggest that antibiotics followed by a live microbiome therapy may be an optimal treatment strategy for rCDI, regardless of number of prior CDI recurrences.
Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature
Rosales, J. Calvo , Ridwan, Ahmad, Ruiz-Orasma, Carlos, Galeano-Lovera, Santiago F. , López, Fernando Gil, Perusina, Jhonny, Squire, Jacqueline D. , Jiang, Liuyan , Moustafa, Muhamad Alhaj , Harris, Dana M. , Iftikhar, Salma , Munipalli, Bala , Cardenas Rosales, Juan Carlos , Gil Lopez, Fernando, Moustafa, Muhamad Alhaj , Harris, Dana M , Ridwan, Ahmad, Gil-López, F. Santoyo, Squire, Jacqueline

Journal of Primary Care & Community Health | July 31, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251360500 | PMID 40741790 Get It

Acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH) is a rare condition characterized by the localized swelling of the deeper skin layers and mucous membranes, especially the face, lips, tongue, throat, and gastrointestinal tract. AAE-C1INH is strongly associated with lymphoproliferative disorders, although it can also be linked to autoimmune conditions, solid tumors, infections, or even occur without an identifiable cause. We present the case of a 45-year-old female patient with complaints of recurrent abdominal pain, bloating, and joint swelling. Laboratory testing showed decreased C1q and C4 complement levels, and C1 esterase inhibitor levels, indicative of AAE-C1INH. Further work up confirmed a diagnosis of extranodal marginal zone lymphoma with involvement of the bone marrow and spleen. Treatment with rituximab led to resolution of angioedema symptoms and almost complete remission of underlying lymphoma. This case underscores the importance of evaluating an underlying lymphoproliferative disorder in AAE-C1INH. Therefore, the early participation of a multidisciplinary team including specialists in immunology, hematology, and oncology is necessary for appropriate management.
Octreotide infusion as a treatment for hepatic hydrothorax in a hospital-at-home program: case report from Mayo Clinic
Webster, Leah W., Wachter, Corey, Turunen, Arto , Nordstrom, Charles W. , Dumic, Igor , Dumic, Igor , Paulson, Margaret R. , Maniaci, Michael J. , Wachter, Corey J., Turunen, Andrew

Therapeutic Advances in Gastroenterology | July 31, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251362573 | PMID 40756179 Get It

Hepatic hydrothorax (HH) is a rare but serious complication of end-stage liver disease that is often refractory to conventional medical and procedural management. This case report describes a 75-year-old woman with HH secondary to cirrhosis from metabolic-associated steatotic liver disease. Her clinical course was marked by recurrent hospitalizations, refractory right-sided pleural effusion, and multiple unsuccessful interventions including diuretics, serial thoracenteses, an indwelling pleural catheter, and chemical pleurodesis. Notably, the persistence of pleural fluid despite resolution of ascites ultimately led to the formation of a thoracic fistula, with pleural drainage volumes exceeding 4 L/day. Further invasive procedures, such as transjugular intrahepatic portosystemic shunt or liver transplantation, were declined by the patient. She was enrolled in Mayo Clinic’s hospital-at-home (HaH) program, where continuous intravenous octreotide was initiated at a dose of 25 mcg/h. This resulted in a significant reduction in pleural output—from over 4000 mL to less than 100 mL daily. After clinical stabilization, the patient transitioned to subcutaneous octreotide and remained clinically stable for over 6 months, with improved quality of life and no significant adverse effects. To our knowledge, this is the first reported case of continuous intravenous octreotide infusion for HH administered safely in a home-based acute care setting. This case underscores the potential therapeutic role of octreotide in managing refractory HH and highlights the feasibility of delivering complex cirrhosis-related care through a HaH model with multidisciplinary collaboration. Further research is warranted to assess the long-term efficacy, safety, and cost-effectiveness of octreotide in this context and to explore broader application in home hospital environments.
Left Atrial Volumetric/Mechanical Coupling Index Is Ready for Prime Time Across Clinical Scenarios
Benfari, Giovanni , Essayagh, Benjamin , Nistri, Stefano , Enriquez‐Sarano, Maurice , Enriquez-Sarano, Maurice , Benfari, Giovanni , Essayagh, Benjamin , Nistri, Stefano , Bursi, Francesca

Journal of the American Heart Association | July 31, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1161/jaha.125.043876 | PMID 40740073 Get It

Preventive effect of postoperative Goreisan administration on symptomatic recurrence of chronic subdural hematoma: a systematic review and meta-analysis
Hong, Sukwoo , Shinya, Yuki , Wang, Zhen , Shinya, Yuki , Wang, Zhen, Bendok, Bernard R. , Saito, Nobuhito

Neurological Research | July 31, 2025 | Volume: 48 | Issue: 6 | Pages: 686-698

10.1080/01616412.2025.2540944 | PMID 40740071 Get It

Assessment of Left Ventricular Global Longitudinal Strain Improvement Following Transcatheter Aortic Valve Replacement
Kassem, Jad , Ghazal, Rachad , Fakhreddin, Omar, Jaber, Farah , Sarkis, Patrick, Yahya, Nabil, Younes, Joe, Francis, Jamil, Sawaya, Fadi , Ghazal, Rachad , Sarkis, Patrick

Journal of Cardiovascular Echography | July 31, 2025 | Volume: 35 | Issue: 2 | Pages: 129-135

10.4103/jcecho.jcecho_99_24 | PMID 40950376 Get It

Background: Transcatheter aortic valve replacement (TAVR) is a well-established therapeutic option for all risk patients with symptomatic severe aortic stenosis (AS). While TAVR primarily addresses AS, its benefits extend beyond the valve itself. Recent studies suggest possible restoration of left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) following TAVR. This study aims to assess changes in LV GLS in patients undergoing TAVR, which may serve as a subclinical indicator of improved LV mechanics. Materials and Methods: This retrospective study included patients with severe AS who underwent TAVR at the American University of Beirut Medical Center from January 2017 to January 2023. Baseline and 1-year echocardiography parameters were compared, and GLS was calculated to assess the impact of TAVR on LV function. Results: A total of 80 patients (mean age: 81.3 ± 7.8 years; 38.8% of women; 88.8% hypertensive) who underwent TAVR for severe AS were included in the final analysis. One-year post-TAVR, echocardiographic studies showed a significant reduction in interventricular septum diameter (13.3 ± 2.3 mm vs. 12 ± 1.8 mm, P < 0.001) and LV mass index (LVMI) (113.6 ± 26.6 g/m 2 vs. 96 ± 30.3 g/m 2 , P < 0.001). LVEF showed a modest improvement (59.2 ± 12.3% vs. 62.1 ± 7.6%, P < 0.01). LV GLS significantly improved from −16.8 ± 4.6% to −19.2 ± 3.3% ( P < 0.001). Baseline LVMI, LVEF, and GLS correlate with the GLS change (ΔGLS) post-TAVR. Conclusion: GLS significantly improves 1 year after TAVR, indicating an overall improvement in LV performance. The degree of improvement in GLS correlates with baseline LVMI and systolic function.
An Integrated Digital Microfluidic Device for the Extraction and Detection of Extracellular Vesicle‐Based Molecules
Lo, Ting‐Wen , Liu, Jing, Zhang, Yuqian , Kim, Yohan , Yao, Janet , Liu, Yuguang , Liu, Yuguang , Liu, Jing, Dong, Haidong , Lucien, Fabrice

Small | July 31, 2025 | Volume: 21 | Issue: 38 | Pages: No page available

10.1002/smll.202504335 | PMID 40739977 Get It

Abstract Extracellular vesicles (EV) are phospholipid‐encapsulated nanoparticles secreted by cells into their surrounding environment. EVs can transfer a variety of biomolecules that mediate intercellular communication and play a key role in physiological and pathological processes. Therefore, EVs are emerging as new biomarkers for diseases, therapeutic targets, and drug delivery vehicles. The isolation and detection of EVs requires time‐consuming and labor‐intensive processes, first to extract EVs from biological and physiological fluids and then to detect EV‐associated molecules with high sensitivity. The methodologies and instruments commonly used for EV analysis are not widely accessible outside of dedicated research laboratories, creating practical barriers for the study of EV‐associated molecules in biology research and clinical applications. To bridge this gap, we developed a proof‐of‐concept digital microfluidic device that can automatedly extract EVs from 20 µL of culture and human plasma samples within 25 min and detect EV‐bound proteins (e.g PD‐L1) on‐chip using an electrochemical sensor. This work serves as a framework for the development of streamlined EV analysis in both research and diagnostics.
Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome
Shim, Kevin G. , Khadarian, Kevork, Samadder, Jewel, Zhou, Jiehao , Shim, Kevin G , Zhou, Jiehao , Yi, Cecilia Arana

Clinical Case Reports | July 31, 2025 | Volume: 13 | Issue: 8 | Pages: No page available

10.1002/ccr3.70602 | PMID 40746769 Get It

ABSTRACTCronkhite‐Canada Syndrome (CCS) is a rare non‐hereditary gastroenterological polyposis syndrome without a clear etiology. Myelodysplastic syndromes (MDS) are clonal hematological disorders. Immune dysregulation has been posited as a contributor to the development of both. A 70‐year‐old man developed chronic diarrhea, dysgeusia, and onycholysis. Endoscopic evaluation and testing to exclude hereditary polyposis syndromes resulted in a diagnosis of CCS. Approximately 1 year later, he was noted to have persistent anemia, which was ultimately diagnosed as MDS. He was evaluated with a myeloid disorder next‐generation sequencing panel and found to have mutations in IDH2, SRSF2, and JAK2. This is the second reported case characterizing concomitant MDS and CCS. This is the first case to report the development of MDS after the diagnosis and treatment of CCS. A successful management strategy for both disorders is outlined within this case report.